



# Supervised Injection Facilities and Other Supervised Consumption Sites: Effectiveness and Value

## Questions for Deliberation and Voting: December 2020 Public Meeting

*These questions are intended for the deliberation of the New England CEPAC voting body at the public meeting.*

**Population for all questions:** All people who inject drugs (PWID) living in an area with access to a syringe service program (SSP) and where a supervised injection facility (SIF) could potentially be placed within a few blocks of where they reside.

### Clinical Evidence

- Given the currently available evidence, is the evidence adequate to demonstrate that the net health benefit of **SIFs** is superior to that provided by **SSPs alone**?

Yes

No

### Potential Other Benefits and Contextual Considerations

- Please vote 1, 2, or 3 on the following potential other benefits and contextual considerations as they relate to **SIFs**. Refer to table below.

Likert Scale of Potential Other Benefits and Contextual Considerations		
1 (Suggests Lower Value)	2 (Neutral)	3 (Suggests Higher Value)
This intervention will not differentially benefit a historically disadvantaged or underserved community.		This intervention will differentially benefit a historically disadvantaged or underserved community.
Uncertainty or overly favorable model assumptions creates significant risk that base-case cost-effectiveness estimates are too optimistic.		Uncertainty or overly unfavorable model assumptions creates significant risk that base-case cost-effectiveness estimates are too pessimistic.
Will not significantly reduce the negative impact of the condition on family and caregivers vs. the comparator.		Will significantly reduce the negative impact of the condition on family and caregivers vs. the comparator.
Will not have a significant impact on improving return to work and/or overall productivity vs. the comparator.		Will have a significant impact on improving return to work and/or overall productivity vs. the comparator.
Other		Other

## Cost Impact

3. Given the currently available evidence, is the evidence adequate to demonstrate that compared with SSPs, **SIFs** are cost-saving?

Yes

No